Medidata, Amgen, Merck & Co, Roche, Ascension, Intermountain and General Electric all took part in a round that boosted Syapse's total funding to almost $70m.
US-based precision medicine developer Syapse received $30m on Tuesday in a series D round backed by a range of corporate investors including clinical trial software provider Medidata Solutions.
Pharmaceutical firms Amgen, Merck & Co and Roche took part through respective subsidiaries Amgen Ventures, Merck Global Health Innovation Fund and Roche Venture Fund.
Ascension Ventures and Intermountain Healthcare Innovation Fund, vehicles for care providers Ascension and Intermountain, also contributed, as did industrial product maker General Electric’s GE Ventures unit, Safeguard Scientifics…
